Taxpayers in developing countries have paid to educate many of those who leave (and who may well end up working in jobs below the level their qualifications would justify at home).
In recent years, to meet requirement of the environmental protection and biological safety, more attention has been paid to develop and use the environment-friendly surfactants.
Although a great deal of attention has been paid to develop novel CeO2-based materials with higher thermal stability and sintering resistance, the decrease in the physical surface area of these catalytic materials is still a major challenge for high-temperature applications.
A considerable body of evidence supports a prominent role for PARs in a variety of human physiological and pathophysiological processes, and thus substantial attention has been paid to develop new drug-like molecules either activating or blocking PARs [ 2].
Driven perhaps by tremendous commercial and research potentials, numerous efforts have been paid to develop retinal OCT, including technical developments and clinical applications.
Currently, more and more efforts in OCT development have been paid to develop ultrahigh speed FDOCT systems capable of >100 kHz A-line rate, i.e., the third generation OCT.
Since the Honda Fujishima effect was reported in 1972, considerable efforts have been paid to develop semiconductor photocatalysts for water splitting and degradation of organic pollutants in order to solve the urgent energy and environmental issues [1 9].
Efforts have thus been paid to develop cost-effective alternatives to WGBS, including various TMS methods based on padlock probes, array capture and solution hybridization capture.
However, the contribution of maternal weight to adverse pregnancy outcomes has not been similarly quantified and less attention has been paid to developing interventions aimed at healthy maternal weight during pregnancy.
Although numerous disease-specific measures of patients' TS and TS-M have been reported in the literature [ 55- 60] less attention has been paid to developing a more general measure of TS-M; one that would permit comparisons across medication types and patient conditions.
